# Immunocore Holdings plc: overview

IMCR · Nasdaq · CIK 1671927 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/imcr.md) · [Financials](/companies/imcr/financials.md) · [Filings](/companies/imcr/filings.md) · [Insiders](/companies/imcr/insiders.md)

Latest reported revenue: [$115.9m](/filings/0001671927-26-000022.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001671927-26-000022).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [80.2](/filings/0001671927-25-000018.md) | [84.1 d](/filings/0001671927-26-000005.md) | [93.9](/filings/0001671927-26-000009.md) | [98.0](/filings/0001671927-26-000022.md) | [104](/filings/0001671927-25-000018.md) | [104 d](/filings/0001671927-26-000005.md) | [107](/filings/0001671927-26-000009.md) | [116](/filings/0001671927-26-000022.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(10.6%)](/filings/0001671927-25-000018.md) | [(23.1%) d](/filings/0001671927-26-000005.md) | [(3.9%)](/filings/0001671927-26-000009.md) | [(15.2%)](/filings/0001671927-26-000022.md) | [(6.9%)](/filings/0001671927-25-000018.md) | [(18.8%) d](/filings/0001671927-26-000005.md) | [6.8%](/filings/0001671927-26-000009.md) | [(2.6%)](/filings/0001671927-26-000022.md) |
| Net margin | % | [10.9%](/filings/0001671927-25-000018.md) | [(28.3%) d](/filings/0001671927-26-000005.md) | [5.4%](/filings/0001671927-26-000022.md) | [(10.5%)](/filings/0001671927-26-000022.md) | [(0.2%)](/filings/0001671927-25-000018.md) | [(28.8%) d](/filings/0001671927-26-000005.md) | [12.2%](/filings/0001671927-26-000022.md) | [(0.7%)](/filings/0001671927-26-000022.md) |
| Diluted EPS | $ per share | [0.17](/filings/0001671927-25-000018.md) | not reported | [0.10](/filings/0001671927-26-000009.md) | [(0.20)](/filings/0001671927-26-000022.md) | [0.00](/filings/0001671927-25-000018.md) | not reported | [0.25](/filings/0001671927-26-000009.md) | [(0.02)](/filings/0001671927-26-000022.md) |
| Free cash flow | $m | [20.3 d](/filings/0001671927-25-000018.md) | [(17.5) d](/filings/0001671927-26-000005.md) | [0.1](/filings/0001671927-26-000009.md) | [25.6 d](/filings/0001671927-26-000022.md) | [(5.2) d](/filings/0001671927-25-000018.md) | [(35.5) d](/filings/0001671927-26-000005.md) | [(15.6)](/filings/0001671927-26-000009.md) | [15.1 d](/filings/0001671927-26-000022.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.1](/filings/0001140361-24-009921.md) | [174](/filings/0001671927-25-000006.md) | [249](/filings/0001671927-26-000005.md) | [310](/filings/0001671927-26-000005.md) | [400](/filings/0001671927-26-000005.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(4281.2%)](/filings/0001140361-24-009921.md) | [(29.7%)](/filings/0001671927-25-000006.md) | [(23.9%)](/filings/0001671927-26-000005.md) | [(22.7%)](/filings/0001671927-26-000005.md) | [(11.3%)](/filings/0001671927-26-000005.md) |
| Net margin | % | [(4414.6%)](/filings/0001140361-24-009921.md) | [(30.1%)](/filings/0001671927-25-000006.md) | [(22.2%)](/filings/0001671927-26-000005.md) | [(16.5%)](/filings/0001671927-26-000005.md) | [(8.9%)](/filings/0001671927-26-000005.md) |
| Diluted EPS | $ per share | [(4.24)](/filings/0001140361-24-009921.md) | [(1.15)](/filings/0001671927-25-000006.md) | [(1.13)](/filings/0001671927-26-000005.md) | [(1.02)](/filings/0001671927-26-000005.md) | [(0.71)](/filings/0001671927-26-000005.md) |
| Free cash flow | $m | [(144)](/filings/0001140361-24-009921.md) | [(51.4)](/filings/0001671927-25-000006.md) | [(2.5)](/filings/0001671927-26-000005.md) | [20.9](/filings/0001671927-26-000005.md) | [(15.1)](/filings/0001671927-26-000005.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/imcr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $181.7m | 5,721,945 |  | Added +1,015,777 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $154.6m | 4,869,798 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $136.8m | 4,307,246 |  | Reduced −521,908 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $115.5m | 3,638,241 |  | Reduced −55,000 |
| [Bellevue Group AG](/funds/1674546.md) | 2026-06-30 | $88.5m | 2,788,245 |  | Reduced −8,558 |
| [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $84.1m | 2,649,368 |  | Unchanged |
| [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $57.1m | 1,800,000 |  | Reduced −966,868 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $52.4m | 1,648,983 |  | Added +627,718 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $50.7m | 1,597,037 |  | Added +359,634 |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $45.3m | 1,428,000 |  | Added +240,000 |

## Recent filings

[All 277 filings](/companies/imcr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-14 | 11:15 ET | [8-K](/filings/0001671927-26-000026.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001671927-26-000026 |
| 2026-08-06 | 11:05 ET | [10-Q](/filings/0001671927-26-000022.md) | Quarterly report, period 2026-06-30 | 0001671927-26-000022 |
| 2026-08-06 | 11:01 ET | [8-K](/filings/0001671927-26-000020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001671927-26-000020 |
| 2026-05-27 | 20:21 ET | [8-K](/filings/0001140361-26-022984.md) | 5.07 Shareholder vote results | 0001140361-26-022984 |
| 2026-05-06 | 11:09 ET | [8-K](/filings/0001140361-26-019205.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-019205 |
| 2026-05-06 | 11:01 ET | [10-Q](/filings/0001671927-26-000009.md) | Quarterly report, period 2026-03-31 | 0001671927-26-000009 |
| 2026-04-16 | 20:05 ET | [DEF 14A](/filings/0001140361-26-015122.md) | Proxy statement, period 2026-05-27 | 0001140361-26-015122 |
| 2026-02-25 | 12:30 ET | [8-K](/filings/0001140361-26-006721.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-006721 |
| 2026-02-25 | 12:01 ET | [10-K](/filings/0001671927-26-000005.md) | Annual report, period 2025-12-31 | 0001671927-26-000005 |
| 2026-01-30 | 12:22 ET | [8-K](/filings/0001140361-26-002894.md) | 5.02 Departure or appointment of officers or directors | 0001140361-26-002894 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001671927-26-000005.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6d0261c6-41dd-41af-91cc-ed6e9f8a9594)

## About the filer

- CIK: 1671927
- Tickers: IMCR
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: X0
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.